⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26613482 | 0.85 | — | — | |
| SCHEMBL129241 | 0.82 | PIK3CD (0.32) | — | |
| SCHEMBL132766 | 0.82 | — | — | |
| SCHEMBL17802141 | 0.79 | TSHR (0.30) | — | |
| SCHEMBL23306 | 0.72 | — | — | |
| SCHEMBL15902312 | 0.72 | — | — | |
| SCHEMBL1456280 | 0.72 | ABCG2 (0.30) | — | |
| SCHEMBL104044 | 0.72 | ABCG2 (0.30) | — | |
| SCHEMBL3979789 | 0.70 | — | — | |
| SCHEMBL6038298 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | claimed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| EP-4013755-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | claimed |
| CN-114585622-A | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | claimed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | claimed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| WO-2021028854-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | claimed |
| US-20080064686-A1 | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-13 | — | — | US | claimed |
| EP-1483265-B1 | PURINE DERIVATIVES AS KINASE INHIBITORS | LILLY CO ELI (US) | 2006-11-22 | — | — | EP | claimed |
| US-20050090483-A1 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY | 2005-04-28 | — | — | US | claimed |
| EP-1483265-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-08 | — | — | EP | claimed |
| WO-2003076442-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | claimed |
| EP-0304138-B1 | PROCESS FOR MAKING 1,3-DIOXANE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-04 | — | — | EP | claimed |
| US-4900846-A | REACTING OXYALDEHYDES WITH ACTIVE PHOSPHOROUS COMPOUND, CYCLIZATION WITH KETONES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-13 | — | — | US | claimed |
| EP-0304138-A1 | Process for making 1,3-dioxane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-02-22 | — | — | EP | claimed |
| US-4772534-A | PHOTORESISTS | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-20 | — | — | US | claimed |
| EP-0142323-A2 | Process for making erythro-dihydroxyalkenoic acide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-05-22 | — | — | EP | claimed |